Cargando…
Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1
The efficacy of immune checkpoint blockade therapy against immunologically “cold” tumors can be enhanced by applying the checkpoint inhibitors in combination with oncolytic viruses. Alternatively, the oncolytic virus construct has been modified to express factors that boost oncolytic virus function....
Autores principales: | Zhu, Yujie, Hu, Xiao, Feng, Lin, Yang, Zhenrong, Zhou, Lulin, Duan, Xinchun, Cheng, Shujun, Zhang, Wen, Liu, Binlei, Zhang, Kaitai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880119/ https://www.ncbi.nlm.nih.gov/pubmed/31788554 http://dx.doi.org/10.1016/j.omto.2019.10.003 |
Ejemplares similares
-
SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment
por: Kong, Defeng, et al.
Publicado: (2022) -
Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018) -
Stability and anti-tumor effect of oncolytic herpes simplex virus type 2
por: Wang, Yang, et al.
Publicado: (2018) -
A Novel Oncolytic Herpes Simplex Virus Type 2 Has Potent Anti-Tumor Activity
por: Zhao, Qian, et al.
Publicado: (2014) -
Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1
por: Zhuang, Xiufen, et al.
Publicado: (2012)